← Back to home

SMALL CELL LUNG CARCINOMA AND OTHER NEUROENDOCRINE NEOPLASMS EXPRESSING DLL3

Clinical trials for SMALL CELL LUNG CARCINOMA AND OTHER NEUROENDOCRINE NEOPLASMS EXPRESSING DLL3 explained in plain language.

Never miss a new study

Get alerted when new SMALL CELL LUNG CARCINOMA AND OTHER NEUROENDOCRINE NEOPLASMS EXPRESSING DLL3 trials appear

Sign up with your email to follow new studies for SMALL CELL LUNG CARCINOMA AND OTHER NEUROENDOCRINE NEOPLASMS EXPRESSING DLL3, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.

Our safety recommendation!

By submitting, you agree to our Terms of use

Trials to join now! 1

New Antibody-Like drug targets tough cancers in first human trial

Disease control Recruiting now

This study tests a new drug called obrixtamig in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker (DLL3). The goal is to find the safest dose and schedule. Participants receive the drug weekly or every 3 weeks for up to 3 yea…

Matched conditions: SMALL CELL LUNG CARCINOMA AND OTHER NEUROENDOCRINE NEOPLASMS EXPRESSING DLL3

Phase: PHASE1 • Sponsor: Boehringer Ingelheim • Aim: Disease control

Last updated May 17, 2026 16:04 UTC

SMALL CELL LUNG CARCINOMA AND OTHER NEUROENDOCRINE NEOPLASMS EXPRESSING DLL3

Get alerted when new SMALL CELL LUNG CARCINOMA AND OTHER NEUROENDOCRINE NEOPLASMS EXPRESSING DLL3 trials appear

New Antibody-Like drug targets tough cancers in first human trial